🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07045857
Recruiting Not applicable

Recurrence of H Pylori : Incidence and Influential Factors.

NCT07045857 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-05-13
Last updated
2025-07-01

Condition(s) studied

H. Pylori Infection

Investigational drug(s) / intervention(s)

follow up of patients that had H. Pylori infection and recieved medical treatment for recurrence

follow up of patients that had H. Pylori infection and recieved medical treatment for recurrence: follow up of patients that had H. Pylori infection and recieved medical treatment for recurrence and influential factors for recurrence

Study summary

This study aims to determine recurrence rates, identify influential factors, investigate key factors that contribute to recurrence, evaluate treatment effectiveness and to assess the efficacy of different eradication regimens and their role in reducing recurrence.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Age: 18-75 years old. * H. pylori infection: Confirmed by endoscopy, biopsy, or non-invasive tests (e.g., urea breath test, stool antigen test). * Symptoms: Presence of dyspepsia, peptic ulcer disease, or other H. pylori-related symptoms. * Laboratory tests: Normal liver and kidney function, and no significant abnormalities in blood counts. Exclusion Criteria: * Patients receiving eradication therapy in the past taking proton pump inhibitors,, H2 blockers ,,bismuth ,, antibiotics or other medications that interfere with the result of the examination in the recent 4 weeks. * Gastrointestinal disorders: Severe gastrointestinal disorders (e.g., gastric cancer, inflammatory bowel disease ,gastric or duodenal ulcer with current or recent bleeding , or clinical significant gastrointestinal bleeding within 4 weeks of randomization). * Malignancies: Active or recent malignancies. * Severe comorbidities: Unstable or severe comorbidities (e.g., heart failure, liver cirrhosis).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Sohag University Hospital Sohag Egypt Recruiting

More Sohag University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07045857 on ClinicalTrials.gov ↗ ← All trials in Egypt